Literature DB >> 1869840

Effect of prior infection with virulent Shigella flexneri 2a on the resistance of monkeys to subsequent infection with Shigella sonnei.

S B Formal1, E V Oaks, R E Olsen, M Wingfield-Eggleston, P J Snoy, J P Cogan.   

Abstract

All virulent shigellae have large plasmids. Plasmid-associated genes encode the expression of membrane-associated proteins (MAP), some of which correlate with the ability to invade susceptible epithelial cells. These MAP are serologically related in all of the shigella serotypes and evoke an antibody response after infection. To determine whether the MAP have a significant role in protection, 24 monkeys were infected with virulent Shigella flexneri 2a. After recovery, one group (with controls) was rechallenged with S. flexneri 2a; another group (with controls) was fed Shigella sonnei. The animals that were rechallenged with S. flexneri 2a were protected, while those that were fed S. sonnei experienced the same incidence of disease as controls. No differences in serum immune response to MAP after primary infection with S. flexneri were detected in immunoblots using lysates of S. flexneri or S. sonnei or in ELISA using water extracts of these strains.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1869840     DOI: 10.1093/infdis/164.3.533

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  54 in total

1.  Myosin-cross-reactive epitope of Shigella flexneri invasion plasmid antigen B.

Authors:  E V Oaks; K R Turbyfill
Journal:  Infect Immun       Date:  1992-02       Impact factor: 3.441

Review 2.  Clinical trials of Shigella vaccines: two steps forward and one step back on a long, hard road.

Authors:  Myron M Levine; Karen L Kotloff; Eileen M Barry; Marcela F Pasetti; Marcelo B Sztein
Journal:  Nat Rev Microbiol       Date:  2007-07       Impact factor: 60.633

3.  Local immune response and protection in the guinea pig keratoconjunctivitis model following immunization with Shigella vaccines.

Authors:  A B Hartman; L L Van de Verg; H H Collins; D B Tang; N O Bendiuk; D N Taylor; C J Powell
Journal:  Infect Immun       Date:  1994-02       Impact factor: 3.441

4.  Development and preclinical evaluation of a trivalent, formalin-inactivated Shigella whole-cell vaccine.

Authors:  R W Kaminski; M Wu; K R Turbyfill; K Clarkson; B Tai; A L Bourgeois; L L Van De Verg; R I Walker; E V Oaks
Journal:  Clin Vaccine Immunol       Date:  2014-01-08

Review 5.  Progress and pitfalls in Shigella vaccine research.

Authors:  Eileen M Barry; Marcela F Pasetti; Marcelo B Sztein; Alessio Fasano; Karen L Kotloff; Myron M Levine
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2013-02-19       Impact factor: 46.802

6.  Specificity of monoclonal antibodies elicited by mucosal infection of BALB/c mice with virulent Shigella flexneri 2a.

Authors:  A B Hartman; L L Van de Verg; C R Mainhart; B D Tall; S J Smith-Gill
Journal:  Clin Diagn Lab Immunol       Date:  1996-09

7.  Safety and immunogenicity of a proteosome-Shigella flexneri 2a lipopolysaccharide vaccine administered intranasally to healthy adults.

Authors:  L F Fries; A D Montemarano; C P Mallett; D N Taylor; T L Hale; G H Lowell
Journal:  Infect Immun       Date:  2001-07       Impact factor: 3.441

8.  Identification of epitope and surface-exposed domains of Shigella flexneri invasion plasmid antigen D (IpaD).

Authors:  K R Turbyfill; J A Mertz; C P Mallett; E V Oaks
Journal:  Infect Immun       Date:  1998-05       Impact factor: 3.441

9.  Virulence, inflammatory potential, and adaptive immunity induced by Shigella flexneri msbB mutants.

Authors:  Ryan T Ranallo; Robert W Kaminski; Tonia George; Alexis A Kordis; Qing Chen; Kathleen Szabo; Malabi M Venkatesan
Journal:  Infect Immun       Date:  2009-11-02       Impact factor: 3.441

10.  Recognition of three epitopic regions on invasion plasmid antigen C by immune sera of rhesus monkeys infected with Shigella flexneri 2a.

Authors:  K R Turbyfill; S W Joseph; E V Oaks
Journal:  Infect Immun       Date:  1995-10       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.